Melanie Quintana

Melanie Quintana

Auto-generated profile, based on publicly available information

Melanie Quintana

Berry Consultants, Austin, Texas

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ASAdam M. Staffaroni
Adam M. Staffaroni
MQMelanie Quintana
Melanie Quintana
BWBarbara Wendelberger
Barbara Wendelberger
HHHilary W. Heuer
Hilary W. Heuer
LRLucy L. Russell
Lucy L. Russell
ABAdam Boxer
Adam Boxer

14 May 2018 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
GWGuoqiao Wang
Guoqiao Wang
SBScott Berry
Scott Berry
CXChengjie Xiong
Chengjie Xiong
JHJason Hassenstab
Jason Hassenstab
MQMelanie Quintana
Melanie Quintana
FUFor The Dominantly Inherited Alzheimer Network Trials Unit
For The Dominantly Inherited Alzheimer Network Trials Unit

26 August 2011 in Genetic Epidemiology
Verified
Journal Article
Closed access
MQMelanie A. Quintana
Melanie A. Quintana
JBJonine L. Berstein
Jonine L. Berstein
DTDuncan C. Thomas
Duncan C. Thomas
DCDavid V. Conti
David V. Conti

31 August 2016 in Trials
Verified
Journal Article
Open access
PDF file
ABAlexandra R. Brown
Alexandra R. Brown
BGByron Gajewski
Byron Gajewski
LALauren S. Aaronson
Lauren S. Aaronson
DMDinesh Pal Mudaranthakam
Dinesh Pal Mudaranthakam
SHSuzanne L. Hunt
Suzanne L. Hunt
RBRichard Barohn
Richard Barohn
In the last few decades, the number of trials using Bayesian methods has grown rapidly. Publications prior to 1990 included only three clinical trials that used Bayesian methods, but that number quickly jumped to 19 in the 1990s and to 99 from 2000 to 2012. While this literature provides many examples of Bayesian Adaptive Designs (BAD), none of the papers that are available walks the reader through the detailed process of conducting a BAD. This paper fills that gap by describing the BAD process used for one comparative effectiveness trial (Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations) that can be generalized for use by others. A BAD was chosen with efficiency in mind. Response-adaptive randomization allows the potential for substantially smaller sample sizes, and can provide faster conclusions about which treatment or treatments are most effective. An Internet-based electronic data capture tool, which features a randomization module, facilitated data capture across study sites and an in-house computation software program was developed to implement the response-adaptive randomization. A process for adapting randomization with minimal interruption to study sites was developed. A new randomization table can be generated quickly and can be seamlessly integrated in the data capture tool with minimal interruption to study sites. This manuscript is the first to detail the technical process used to evaluate a multisite comparative effectiveness trial using adaptive randomization. An important opportunity for the application of Bayesian trials is in comparative effectiveness trials. The specific case study presented in this paper can be used as a model for conducting future clinical trials using a combination of statistical software and a web-based application. ClinicalTrials.gov Identifier: NCT02260388 , registered on 6 October 2014

3 December 2018 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
MQM. Quintana
M. Quintana
JSJ. Shrader
J. Shrader
CSC. Slota
C. Slota
GJG. Joe
G. Joe
JMJ.C. McKew
J.C. McKew
NCN. Carrillo
N. Carrillo

7 January 2015 in Statistics in Medicine
Verified
Journal Article
Open access
PDF file
BGByron Gajewski
Byron Gajewski
SBScott M. Berry
Scott M. Berry
MQMelanie Quintana
Melanie Quintana
MPMamatha Pasnoor
Mamatha Pasnoor
MDMazen Dimachkie
Mazen Dimachkie
RBRichard Barohn
Richard Barohn
The time is right for the use of Bayesian Adaptive Designs (BAD) in comparative effectiveness trials. For example, Patient Centered Outcomes Research Institute has joined the Food and Drug Administration and National Intitutes of Health in adopting policies/guidelines encouraging their use. There are multiple aspects to BAD that need to be considered when designing a comparative effectiveness design. First, the adaptation rules can determine the expected size of the trial. Second, a utility function can be used to combine extremely important co‐endpoints (e.g., efficacy and tolerability) and is a valuable tool for incorporating clinical expertise and potentially patient preference. Third, accrual rate is also very, very important. Specifically, there is a juxtaposition related to accrual and BAD. If accrual rate is too fast we never gain efficient information for adapting. If accrual rate is too slow we never finish the clinical trial. We propose methodology for finding the ‘sweet spot’ for BAD that addresses these as design parameters. We demonstrate the methodology on a comparative effectiveness BAD of pharmaceutical agents in cryptogenic sensory polyneuropathy. The study has five arms with two endpoints that are combined with a utility function. The accrual rate is assumed to stem from multiple sites. We perform simulations from which the composite accrual rates across sites result in various piecewise Poisson distributions as parameter inputs. We balance both average number of patients needed and average length of time to finish the study. Copyright © 2015 John Wiley & Sons, Ltd.